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Vaccinia-related kinase 3 (VRK3), previously characterized as a direct activator of vaccinia H1-related (VHR) phosphatase, inactivates
extracellular signal-regulated kinase (ERK) in the nucleus of neuronal cells. Here we show that VRK3 is expressed in various other rodent tissues and
in embryos, and regulates VHR phosphatase activity in these tissues. We observed colocalization of VRK3 and VHR in the testis tissue and could
detect protein complex containing VRK3, VHR and ERK in immunoprecipitation analysis. Notably, the addition of recombinant VRK3 protein to
total protein lysates, obtained either from adult tissues or embryos, enhanced the phosphatase activity of VHR, but not the activity of MKP3. The
results further indicate that the VHR–VRK3 complex is a phosphatase-active form. In addition, we found that VRK3 can regulate EGF-induced
cellular growth signaling that is mediated by ERK activation. Our results suggest that in addition to neuronal cells, various other rodent adult tissues
and embryos possess a common signaling mechanism which is involved in an indirect regulation of ERK activity by VRK3-mediated VHR activity.
© 2007 Elsevier B.V. All rights reserved.Keywords: Vaccinia-related kinase 3; Vaccinia H1-related phosphatase; Extracellular signal-regulated kinase; Mitogen-activated protein kinase phosphatase1. Introduction
There are three members of the vaccinia-related kinase
(VRK) Ser/Thr protein kinase family in mammals: VRK1,
VRK2 and VRK3 [1,2]. VRK1 participates in the regulation of
the cell cycle progression, particularly during mitosis, and its
Drosophila homolog (known as nucleosomal histone kinase 1
(NHK1)), functions as a histone kinase in this process [3].
Recently we characterized the cellular function of VRK1 as a
mitotic histone kinase. We demonstrated that VRK1 is involved
in chromatin condensation by directly phosphorylating the
histone H3 at its Thr3 and Ser10 residues during G2- to M-
phase transition [4]. VRK1 is also known to regulate nuclear
envelope assembly during mitosis by regulating the phosphor-
ylation status of the barrier-to-autointegration factor (BAF) [5].
In addition, VRK1 is known to phosphorylate novel regulatory
residues, and therefore increases the stability and activity of
several transcriptional factors including p53 [6,7], ATF2 [8] and
cJun [9].⁎ Corresponding author. Tel.: +82 54 279 2297; fax: +82 54 279 2199.
E-mail address: ktk@postech.ac.kr (K.-T. Kim).
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of human VRK2, including VRK2A and VRK2B, demonstrate
that VRK2A is found in the cytoplasm surrounding the
endoplasmic reticulum and mitochondria, whereas VRK2B
localizes not only to the nucleus but also to the cytoplasm [10].
These studies found that VRK2A is expressed in all cell types
tested, whereas VRK2B is expressed in cell lines in which
VRK1 is localized to the cytoplasm [10]. In the nucleus,
VRK2B can phosphorylate tumor suppressor protein p53 at
Thr18, suggesting that it may complement the activity of VRK1
[10]. Given the high amino acid sequence identity in the kinase
domain of VRK1 and -2, they are believed to have some
common substrates such as BAF [5] and p53 [10]. In contrast,
both the kinase domain and the non-kinase regulatory domain of
VRK3 are quite different from those of VRK1 and -2 [1].
Although vaccinia H1-related (VHR) phosphatase, an atypical
mitogen-activated protein kinase (MAPK) phosphatase (MKP),
is known to interact with VRK3 [11], no known VRK3
substrates have been identified to date.
The duration of activation and the subcellular localization of
ERK pathway must be tightly controlled. This is important in
order to guarantee the fidelity of integrated biological responses
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proliferation, differentiation and development [12,13]. Upon
activation, ERK translocates to the nucleus and induces the
expression of genes required for unique physiological processes
by phosphorylating stimuli-specific transcription factors
[14,15]. In contrast, MKPs negatively regulate MAPK activity
by dephosphorylating critical phospho-residues required for the
MAPK activation, and play an important role in determining the
magnitude and duration of MAPK activity [16]. A dozen MKPs
have been identified to date, and are distinguished by differences
in their MAPK specificity and subcellular localization [17,18].
Based on their expression profiles,MKPs are largely categorized
into two groups: inducible or constitutive. The genes of
inducible MKPs, such as MKP1 and MKP2, are immediately
expressed uponMAPKs activation, forming a negative feedback
loop. After transient expression, they are rapidly degraded in a
proteasome-dependent manner via MAPK-induced phosphor-
ylation of MKP [19,20]. In contrast, constitutively expressed
MKPs, such as VHR [11,21,22] andMKP3 [23], are responsible
for the maintenance of MAPKs activity in quiescent cells as well
as stimulated cells. The enzymatic properties ofMKP3 andVHR
seem somewhat different. MKP3 generally exists in an active
state [24], whereas VHR remains rather inactive in resting cells,
or at least in neuronal cell lines such as PC12 and HT22 cells, as
well as in the Jurkat T immune cell line [11,22]. Recently we
disclosed the molecular mechanism by which VRK3 modulates
VHR activation [11]. Upon stimulation of the ERK pathway, the
transcription of VRK3 is induced. In terms of a negative feed-
back system, we found that ERK activity was downregulated by
VRK3-mediated VHR phosphatase activation which specifi-
cally targets phospho-ERK [11]. In T-cells, an alternative VHR
activation mode is accomplished by a protein tyrosine kinase
called ZAP70 that is involved in T-cell receptor activation, via
Tyr138 phosphorylation of VHR [22]. Meanwhile, a recent
study has revealed a role for VHR in cell cycle progression.
During the cell cycle, VHR protein expression varies such that
its expression peaks in the mitotic phase compared to the G1
phase [25]. Importantly, depletion of VHR expression using
RNA interference results in sustained activation of ERK and
JNK, causing cell cycle arrest at the G1/S or G2/M transitions,
and also induces cellular senescence [25].
In the present study, we provide evidence that VRK3 regu-
lates VHR activity in various tissues obtained from adult and
embryo rodents. Our results demonstrate that VRK3 is a direct
activator of VHR and negatively regulates ERK signaling in
vivo.
2. Materials and methods
2.1. Northern analysis
Tissues from 2-month-old male BALB/c mice were homogenized by
grinding in the presence of liquid nitrogen. Total RNA from homogenates wasFig. 1. Tissue distribution of mouse VRK3. (A) Northern blotting with an anti-sens
(rRNA) was used as a loading control. (B) Localization of VRK3 mRNA in kidney
(bottom panels). (C) Localization of VRK3 protein was analyzed by immunohistoch
DNA (blue, Hoechst) and DIC (differential interference contrast).isolated using the TRI reagent (Molecular Research Center), according to the
manufacturer's instructions. A probe corresponding to nucleotides 1261–1650
of VRK3 (NCBI accession number BC024839) was generated by PCR
amplification, and radioisotope-labeled by random primer extension (Boehrin-
ger Mannheim). Probes were purified using a push column beta shield device
and NucTrap probe purification columns (Stratagene). An aliquot of total RNA
(5 μg) was subjected to Northern blot analysis. Following hybridization,
washing and detection procedures were performed, as described previously [26].
2.2. In situ hybridization
The mice were perfused intracardially with 0.1 M phosphate buffered saline
(PBS), pH 7.2, followed by a fixative consisting of 4% paraformaldehyde in
0.1 M sodium phosphate, pH 7.2. Tissues were cryo-sectioned at up to 4 μm in
thickness then mounted onto poly-lysine-coated slides. Tissue sections were
deparaffinized, dehydrated, and incubated with either sense or anti-sense
riboprobes, prepared as described below.
The probe (nucleotides 1261–1650 of VRK3) for Northern blot analysis was
subcloned into pGEM-T Easy vector (Promega), and transcribed by T7 or SP6
RNA polymerase, to generate sense or anti-sense riboprobes, respectively.
Riboprobes were purified using a probe purification column (Stratagene), and
then used for in situ hybridization analysis. Following hybridization, washing
and detection procedures were performed as described previously [27].
2.3. Immunohistochemistry
Tissue sections, prepared during in situ hybridization, were incubatedwith an
anti-VRK3 or an anti-VHR antibody, followed by incubation with fluorescence-
labeled secondary antibodies. DNAwas counterstained with 20 ng/ml of Hoechst
dye. AnAxioplan2 fluorescence imagingmicroscope (Carl Zeiss), equippedwith
an ApoTome (Carl Zeiss), was used for obtaining fluorescence or differential
interference contrast images.
2.4. Rat embryos
Rat embryos were obtained from Sprague–Dawley rats (Hyochang Science,
Daegu, Korea), sacrificed at days 13 to 17, and various organs were collected
and analyzed.
2.5. Immunoblotting
Total protein lysates were prepared in lysis buffer (20 mM HEPES, pH 7.6,
250 mM NaCl, 1.5 mM MgCl2, 2 mM EDTA, 20% Glycerol, 0.1% Nonidet P-
40, 1 mM dithiothreitol (DTT), protease inhibitor cocktail (Roche) and 200 μM
PMSF), subjected to SDS-PAGE, and transferred to nitrocellulose membranes.
Blots were incubated with specific antibodies, including VRK1, VRK2 and
VRK3 antisera that were prepared using an established protocol [11]. Other
antibodies used were anti-VHR (BD Bioscience), -ERK1/2, -phospho-ERK1/2,
-phospho-JNK, -phospho-p38 (Cell Signaling Technology), anti-MKP1, -MKP2
and -PCNA (Santa Cruz Biotechnology), anti-MKP3 (Proteintech Group, Inc),
anti-phospho histone H3 Ser10 (Upstate) and anti-glyceraldehyde 3-phosphate
dehydrogenase (Calbiochem).
2.6. Immunoprecipitation
For immunoprecipitation, protein lysates from mouse testes were incubated
for 2 h at 4 °C with protein-G sepharose (Amersham), and rat preimmune serum
or mouse immunoglobulin G1 was used for pre-clearing. The supernatants were
transferred to a new tube, and incubated overnight at 4 °C either with rat anti-
VRK3 or with mouse anti-VHR antibody. Protein-G sepharose beads were
added, incubated for 2 h at 4 °C, washed, and the bound proteins were thene VRK3 probe. Ethidium bromide (EtBr)-stained 18S and 28S ribosomal RNA
and testis was detected with anti-sense (upper panels) or sense VRK3 probes
emistry with an anti-VRK3 antibody in kidney and testis. VRK3 (red or green),
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Fig. 2. Ternary complex containingVRK3, VHR, and ERK inmouse testis. Total
lysates from mouse testis were analyzed by immunoprecipitation with an anti-
VRK3 antibody (A) or with an anti-VHR antibody (B). Coimmunoprecipitated
proteins were detected using specific antibodies as indicated. PIS (preimmune
serum), mIg-G1 (mouse immunoglobulin G1), Ig HC (immunoglobulin heavy
chain) and Ig LC (immunoglobulin light chain). (C) Immunohistochemistry of
mouse testis to detect VRK3 (red) and VHR (green). ST; seminiferous tubule,
IC; interstitial cells, DIC; differential interference contrast.
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analyzed by immunoblotting with specific antibodies.
2.7. Phosphatase activity assay
VHR or MKP3 proteins were immunoprecipitated from 500 μg of total
lysates of tissues or embryos. Immunoprecipitated VHR or MKP3 was then
incubated for the indicated period of time (hours) or for 3 h at 30 °C in
phosphatase reaction buffer (50 mM Tris pH 7.5, 5 mM MgCl2, 0.5 mM DTT
and 150 mM KCl) containing 500 ng of recombinant phosphorylated ERK2
protein as substrate (a gift from Dr. H. S. Yoon, Nanyang Technological
University, Singapore). The residual phospho-ERK2 protein level was detected
by immunoblotting with an anti-phospho-ERK antibody. The total ERK2
quantity, which served as a loading control, was also measured with a non-
phospho anti-ERK antibody.
2.8. Cell culture and transfection
HT22 cells were grown in Dulbecco's Modified Eagle Medium (DMEM)
supplemented with 10% fetal bovine serum (FBS) and 100 U/ml each of
penicillin G and streptomycin. Transient transfection of HT22 cells was carried
out with Metafectine Reagent (Biontex) as described in the manufacturer's
protocol. The siRNA duplex targeting VRK3 (siVRK3; GAGUUCAUUAG-
CAUGGACC), and the scrambled siRNA (siCont; CTGUUCAAUUACGAG-
CAGU) were obtained from Dharmacon.
3. Results
3.1. Tissue distribution of mouse VRK3
VRK3 cooperates with VHR to negatively regulate nuclear
ERK in resting or nerve growth factor-stimulated neuronal cells
[11]. ERK is expressed in almost all cell types, and plays a key
role in numerous cellular functions [28]. Accordingly, we
wondered whether the interplay between VRK3 and VHR also
exists in tissues other than neuronal cells. To test this possibility,
we first determined the level of VRK3 and VHR expression in
various mouse tissues. The mRNA expression level of VRK3
was initially assessed by Northern blotting. The results revealed
abundant levels of VRK3 mRNA expression in the testis and
kidney tissue, but very little VRK3 mRNA expression in the
skeletal muscle (Fig. 1A). Most other tissues examined dis-
played moderate VRK3 expression (Fig. 1A). In situ hybridiza-
tion was performed to determine the mRNA localization of
VRK3 in the tissues that expressed the highest level of VRK3
(testis and kidney). In the kidney tissue, the VRK3 mRNA
signal was preferentially localized to the cortex region, and was
hardly detectable in the medulla region (Fig. 1B). Immunohis-
tochemical analysis yielded similar results to in situ hybridiza-
tion and confirmed that cortex-rich expression of VRK3 exists
(Fig. 1C). In the testis tissue, VRK3 expression was detected
mainly in the interstitial tissues consisting of Leydig cells,
which are responsible for the production of male hormones,
while in seminiferous tubules, which contain Sertoli and
spermatogenic cells, VRK3 was hardly detectable (Fig. 1C).
Previous studies have detected relatively high levels of VRK3
during mouse hematopoietic development, indicating that
VRK3 expression is associated with cellular proliferation [2].
Of the adult mouse tissues, the testis is known to undergo
continuous proliferation. Indeed, the markers of cell prolifera-tion such as phospho-histone H3 and proliferating cell nuclear
antigen (PCNA) were prominent in the testis (Fig. 1D). As
shown in Fig. 1D, the level of VRK3 was very heterogeneous,
while VHR had relatively similar levels in all tissues tested.
However, it is striking that the levels of VRK3 in both testis
and kidney were very high, but the proliferation markers were
only detected in the testis (Fig. 1D). The results suggest that
VRK3 level is not directly correlated with cell proliferation.
Tissue distribution analyses revealed ubiquitous expression of
VRK3, implying its general and various physiological functions
in vivo.
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In the previous report, we found a ternary complex containing
VRK3, VHR and ERK in neuronal cells [11]. To determine
whether this protein complex also exists in other tissues besides
neuronal cells, we prepared protein lysates frommouse testis and
carried out immunoprecipitation analysis. Not surprisingly,
VHR and ERKwere found in immunoprecipitates prepared with
an anti-VRK3 antibody, while other MKPs including MKP1,
MKP2 and MKP3 were not detected (Fig. 2A). In turn, when
VHR was pulled-down, co-precipitated VRK3 and ERK were
detected, whereas other VRK isotypes such as VRK1 and VRK2
were undetectable (Fig. 2B). Immunohistochemical analysis
revealed that both VRK3 and VHR were expressed dominantly
in the interstitial cells but significant amounts of VHR were alsoFig. 3. VRK3, MAPKs and MKPs protein expression and activity assay of constitutiv
and testis were analyzed by immunoblotting with the indicated antibodies. The
(B, C) Immunoprecipitated VHR (B) or MKP3 (C) activity assay from mouse tiss
substrate, was measured. VHR or MKP3 levels from immunoprecipitates are show
represent means±S.D. (n=3).detected in the seminiferous tubules of the testis tissue (Fig. 2C).
These results show that VRK3 assembles specifically with VHR
in mouse tissues.
3.3. VHR phosphatase activity in mouse tissues
VRK3 mediates ERK inactivation via direct binding to VHR
phosphatase in a concentration-dependent manner both in vitro
and in vivo [11,29]. To investigate the relationship between
VRK3 expression and ERK activity in various mouse tissues,
we measured the protein levels of VRK3, VHR and phospho-
ERK. Interestingly, the activity of ERK was inversely propor-
tional to VRK3 expression in the tested tissues, whereas a
relationship between JNK or p38 MAPK and VRK3 expression
was not evident (Fig. 3A). Of importance is the finding that theely expressed MKPs in mouse tissues. (A) Total lysates from mouse liver, kidney
level of GAPDH was used to normalize the loading quantity of lysates.
ues. The ratio of dephosphorylated/phosphorylated ERK2 proteins, used as a
n. (D) Phosphatase activity of VHR from different tissues. Error bars in B–D
Fig. 4. Essential role of VRK3 in VHR activation. (A) Each recombinant protein
(as indicated) was added to the total protein liver extracts for 12 h, VHR
phosphatase activity assays were performed in vitro, and immunoprecipitation of
VHR was performed using a specific antibody against VHR. (B) VHR activity
was assessed as in (A) except that increasing concentrations ofGSTorGST-VRK3
protein were added. (C) The bound-VRK3, obtained in the VHR-immune
complex from (B), was detected by immunoblotting with an anti-VRK3 antibody.
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protein levels, showed decreased levels of phospho-ERK,
whereas the liver, which had lower VRK3 levels, showed
elevated levels of active ERK. To determine the MKP respon-
sible for the maintenance of basal phospho-ERK levels in those
tissues, we measured the expression levels of MKPs by
immunoblotting. The expression of inducible MKPs (MKP1
and MKP2), whose activities are dependent on their expression,
was associated with phospho-ERK levels. In contrast, VHR and
MKP3 were expressed rather evenly in all three tissues, except
for the presence of slightly higher MKP3 levels in the testis
(Fig. 3A). These results suggest that inducible MKPs are not
responsible for the basal ERK activity in adult mouse tissues.
Thus, we shifted our attention to the activity of constitutively
expressed MKPs. Immunoprecipitated VHR (Fig. 3B) or MKP3
(Fig. 3C) was used to assess phosphatase activity by measuring
the dephosphorylation/phosphorylation ratio of recombinant
phospho-ERK2 proteins as substrate. The VHR levels in the
precipitates were similar, but the phosphatase activities were
distinct among the three tissues tested (Fig. 3B). Specifically,
the VHR activity in the kidney and testis (which have abundant
VRK3 expression) was more prominent than that observed in
the liver (which has low VRK3 expression) (Fig. 3B).
When we investigated the activity of MKP3 in various
tissues, we found that the activity of MKP3 differs for each
tissue type, but no correlation with the endogenous phospho-
ERK levels was observed (Fig. 3C). Given our observation of
similar VHR levels but different phosphatase activities in
different tissues, we were interested in determining the source of
the variations in phosphatase activity. To this end, we measured
the VHR phosphatase activity and found that this activity
increased in a time-dependent manner in all three tissues tested
(Fig. 3D). We further demonstrated that the VHR activity
present in the kidney and testis is dramatically increased com-
pared to that observed in the liver. These results show that the
intrinsic activity of VHR varies from tissue to tissue, and that
this activity is closely correlated with the basal ERK activity in
mouse tissues.
3.4. Enhanced VHR activity is mediated by VRK3 in mouse
tissues
Given that the activity of ERK is directly affected by VHR
activity, and is linked to VRK3 expression, we tested if VRK3
can modulate VHR activity in vivo. To confirm this possibility,
we prepared purified GST, GST-VRK1, GST-VRK3 or GST-
VRK3-KD (kinase-dead) mutant proteins and added each
protein to total liver tissue lysates. The effect of adding the
purified protein was assessed by measuring the phosphatase
activity following immunoprecipitation with VHR. Addition of
GST or GST-VRK1 did not alter the VHR activity, whereas
GST-VRK3 or GST-VRK3-KD markedly increased VHR
activity (Fig. 4A). Moreover, VRK3 increased VHR phospha-
tase activity in a concentration-dependent manner (Fig. 4B). An
in vitro binding assay also showed a correlation between VHR
activity and the level of associated-VRK3 (Fig. 4C). Thus, these
results extend our previous in vitro observations and show thatVRK3 upregulates VHR phosphatase activity in various other
cell systems through a direct interaction.
3.5. Correlation between VRK3 expression and VHR activity
during rat embryo development
Next, we examined embryos in order to investigate the in-
volvement of VHR during development, since embryonic tissues
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expression of VRK3, VHR and ERK in embryos, total protein
lysates were prepared from rat embryos at different develop-
mental stages (embryonic days 13 to 17). Interestingly immuno-
blotting experiments showed that VRK3 and phospho-ERK
levels changed between embryonic stages (Fig. 5A). As an
embryo matured, the VRK3 expression increased gradually, but
the level of phospho-ERK decreased (Fig. 5A). In contrast,
the level of VHR protein was similar throughout embryonic
maturation, whilst the expression of other MKPs, including
MKP1, MKP2 and MKP3, differed between embryonic stagesFig. 5. VRK3 is required for VHR-mediated ERK inactivation during embryo develop
the indicated antibodies. (B) Immunoprecipitated MKP3 or VHR phosphatase activ
ERK2 protein used as a substrate. (C, D) Modulation of VHR (C) or MKP3 (D) p
increasing amounts of GST (control) or GST-VRK3 protein.(Fig. 5A). Given the finding that the level of inducible MKPs,
such as MKP1 and MKP2, did not show a significant correlation
with the level of phospho-ERK, we measured constitutively
expressed MKPs such as VHR and MKP3. While the activity of
MKP3 was dependent on its expression level (Fig. 5B), the
activity of VHR gradually increased despite the fact that the VHR
protein level did not vary considerably during embryonic
development (Fig. 5B). Thus, of the tested MKPs, the VHR
activity seemed to reflect the basal ERK activity in these embryos.
To investigate whether VRK3 can modulate VHR activity in
this system, similar experiments to those described in Fig. 4Bment. (A) Total lysates from rat embryos were analyzed by immunoblotting with
ity was determined by analyzing the ratio of dephosphorylated/phosphorylated
hosphatase activity was assessed by an in vitro phosphatase assay containing
Fig. 6. Potentiation of ERK signaling by knock-down of VRK3. HT22 cells
were transfected with either control siRNA or siRNA targeting VRK3 for 24 h
and then treated with EGF for the indicated times. Total cell lysates were
analyzed by immunoblotting with the indicated antibody. The level of phospho-
ERK and phospho-Elk1 was quantitated and depicted.
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is markedly enhanced by the addition of recombinant VRK3
protein in a concentration-dependent manner (Fig. 5C). In con-
trast, the addition of the GST control failed to activate VHR
(Fig. 5C).We further found thatMKP3 activity was not altered by
the addition of GST-VRK3 protein (Fig. 5D), suggesting that
VRK3 can indirectly modulate ERK activity by activating VHR
in embryos.
3.6. Potentiation of EGF-induced ERK activity by knock-down
of VRK3
Stimulation of cells with epidermal growth factor (EGF) can
induce transient activation of ERK within several minutes and
induce cell growth [29]. To examine if VRK3 can inhibit the
EGF-induced cellular growth signal, we measured ERK activity
by measuring the levels of phospho-ERK and phospho-E28 like
kinase1 (Elk1). Elk1 is well characterized as a nuclear target of
active ERK under growth conditions [30,31,32]. Stimulation of
EGF in VRK3-depleted cells resulted in more potent and
sustained ERK activation as well as rapid elevation of phospho-
Elk1 was detected compared to control siRNA-treated cells
(Fig. 6).
4. Discussion
In the present study, we observed abundant VRK3 expres-
sion in the renal cortex and Leydig cells of rodent testes. In the
renal cortex, the ERK pathway is implicated in numerous dis-
eases such as diabetic renal hypertrophy, diabetic nephropathy,
and glomerulosclerosis [33,34,35]. Additionally, ERK has
been suggested to play a role in renal development, particularly
during glomerulonephrogenesis [36,37]. On the other hand,
the ERK pathway is implicated in the production of steroid
hormones [38,39] and the regulation of morphological changesin Leydig cells of the testis [40]. Further studies are required to
determine the delicate functions of VRK3 in particular tissues
and cells, in order to elucidate its precise physiological role in
these systems.
We found that the VRK3 protein level directly affected the
phosphatase activity of VHR, resulting in reduced ERK activity
in both adult tissues and embryos. During embryonic develop-
ment, VRK3 expression gradually increased whereas ERK
activity was decreased progressively. This suggests that VRK3
may play a role in various developmental processes such as
proliferation and differentiation by regulating ERK activity.
More direct evidence for the role of VRK3 in the activation of
VHR in vivo could be obtained using VRK3 knock-out mice.
Typical MKPs are composed of two domains: a dual-
specificity phosphatase (DUSP) domain and a MAPK-binding
(MKB) domain. The DUSP domains of all MKPs share strong
homology with each other, while the MKB domain plays a
major role in regulating their enzymatic specificity by inter-
acting with MAPKs. The MKB domain contains a cluster of
positively charged amino acids, which are involved in deter-
mining the binding specificity of MKPs to MAPKs [41,42].
Binding of phosphorylated MAPK to the MKB domain alters
the structure of the DUSP domain. This conformational change,
along with the interaction of the MKP's catalytic domain with
MAPK, greatly enhances the catalytic activity of MKPs [43,44].
The atypical MKP, VHR has a DUSP domain but not a MKB
domain [17]. Nevertheless, VHR binds to MAPKs, especially
ERK with exquisite specificity [11,21]. As the DUSP domain
alone is not enough to selectively distinguish between MAPKs,
we speculated that an auxiliary factor imparts MAPK specificity
to VHR. From this view point, it is possible that VRK3 func-
tions as the MKB domain of VHR, and thus VRK3 confers its
MAPK specificity to VHR. Further studies are required to
identify the binding partners of low molecular weight, atypical
MKPs, such as MKP6 and MKP8. The role of these factors as
MKB domains for specific atypical MKPs will provide
important insights into the validity of this hypothesis.
ERK acts as the core protein kinase that links various extra-
cellular stimuli to diverse intracellular physiological responses.
Such responses range from gene expression outcomes to
decisions made on the fate of a cell [12,13,28]. Constitutive
activation of ERK is commonly detected in human tumors, and
the protein is therefore an attractive target for anticancer drug
development [45,46]. It is speculated that specific inhibition of
the ERK pathway blocks abnormal mitogenic signals, metas-
tasis, and angiogenesis in tumors [45,46]. In fact, several
inhibitors targeting specific protein kinases in the growth factor-
ERK pathway, including RAF and MEK, are currently under
development for clinical trials. Here, we propose that VRK3,
which activates VHR in a concentration-dependent manner,
provides an alternative avenue to alleviate aberrantly upregu-
lated ERK activity. We show here that in both adult and
embryonic tissues, VHR significantly contributes to the
maintenance of basal ERK activity. VRK3 plays a critical role
as a limiting factor of VHR activation since VHR activation is
achieved in various tissues by the addition of recombinant
VRK3 protein. Hence, regulating ERK, via VRK3-mediated
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treating various pathological conditions caused by abnormal
ERK signaling.
Here, we demonstrate that VRK3 is expressed in various
adult tissues and embryos, and that VRK3 enables VHR to play
an essential role in negatively affecting ERK activity. VRK3 can
therefore be utilized to develop effective modulators of various
pathological conditions caused by deregulation of ERK.
Collectively, our results indicate that VRK3 is a critical regulator
of ERK signaling and confersMAPK specificity to VHR in vivo.
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